


{
  "A.2 EudraCT number": "eudract_number",
  "National Competent Authority": "national_competent_authority",
  "Clinical Trial Type": "clinical_trial_type",
  "Trial Status": "trial_status",
  "Date on which this record was first entered in the EudraCT database": "last_updated_date",
  "A.1 Member State Concerned": "member_state_concerned",
  "A.3 Full title of the trial": "trial_title",
  "A.3.1 Title of the trial for lay people, in easily understood, i.e. non-technical, language": "simple_trial_title",
  "A.3.2 Name or abbreviated title of the trial where available": "abbreviated_trial_title",
  "A.4.1 Sponsor's protocol code number": "sponsor_protocol_code_number",
  "A.5.1 ISRCTN (International Standard Randomised Controlled Trial) Number": "isrctn_id",
  "A.5.2 US NCT (ClinicalTrials.gov registry) number": "nct_id",
  "A.5.3 WHO Universal Trial Reference Number (UTRN)": "who_id",
  "A.5.4 Other Identifier - Name": "other_id_name",
  "A.5.4 Other Identifier - Identifier": "other_id_identifier",
  "A.8 EMA Decision number of Paediatric Investigation Plan": "paediatric_decision_number",
  "B.1.1 Name of Sponsor": "sponsor_name",
  "B.1.3.4\tCountry": "sponsor_country",
  "B.3.1 and B.3.2\tStatus of the sponsor": "sponsor_status",
  "B.4.1 Name of organisation providing support": "monetary_support_organization",
  "B.4.2 Country": "monetary_support_organization_country",
  "B.5.1 Name of organisation": "trial_contact_point_name",
  "B.5.2 Functional name of contact point": "trial_contact_point_functional_name",
  "B.5.3.1 Street Address": "trial_contact_point_street_address",
  "B.5.3.2 Town/ city": "trial_contact_point_city",
  "B.5.3.3 Post code": "trial_contact_point_post_code",
  "B.5.3.4 Country": "trial_contact_point_country",
  "B.5.4 Telephone number": "trial_contact_point_telephone",
  "B.5.5 Fax number": "trial_contact_point_fax",
  "B.5.6 E-mail": "trial_contact_point_email",
  "D.2 Status of the IMP to be used in the clinical trial": "trial_imp_status",
  "D.2.1 IMP to be used in the trial has a marketing authorisation": "trial_imp_has_marketing_authorization",
  "D.2.1.1.1 Trade name": "trial_imp_trade_name",
  "D.2.1.1.2 Name of the Marketing Authorisation holder ": "trial_imp_marketing_authorization_holder_name",
  "D.2.1.2 Country which granted the Marketing Authorisation": "trial_imp_marketing_authorization_holder_country",
  "D.2.5 The IMP has been designated in this indication as an orphan drug in the Community": "imp_is_orphan_drug",
  "D.2.5.1 Orphan drug designation number": "imp_is_orphan_designation_number",
  "D.3.1 Product name": "imp_product_name",
  "D.3.2 Product code": "imp_product_code",
  "D.3.4 Pharmaceutical form": "imp_pharmaceutical_form",
  "D.3.4.1 Specific paediatric formulation": "trial_has_specific_paediatric_formulation",
  "D.3.7 Routes of administration for this IMP": "trial_imp_routes_of_administration",
  "D.3.8 INN - Proposed INN": "trial_proposed_inn",
  "D.3.9.1 CAS number": "trial_cas_number",
  "D.3.9.2 Current sponsor code": "trial_current_sponsor_code",
  "D.3.9.3 Other descriptive name": "trial_other_descriptive_name",
  "D.3.9.4 EV Substance Code": "trial_ev_substance_code",
  "D.3.10.1 Concentration unit": "trial_dosage_concentration_unit",
  "D.3.10.2 Concentration type": "trial_dosage_concentration_type",
  "D.3.10.3 Concentration number": "trial_dosage_concentration_number",
  "D.3.11.1 Active substance of chemical origin": "imp_contains_active_chemical_origin",
  "D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)": "imp_contains_active_biological_origin",
  "D.3.11.3 Advanced Therapy IMP (ATIMP)": "imp_contains_advanced_therapy_origin",
  "D.3.11.3.1 Somatic cell therapy medicinal product": "imp_contains_somatic_cell_product",
  "D.3.11.3.2 Gene therapy medical product": "imp_contains_gene_therapy_product",
  "D.3.11.3.3 Tissue Engineered Product": "imp_contains_tissue_engineered_product",
  "D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device)": "trial_contains_combination_atimp",
  "D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product": "trial_has_cat_number",
  "D.3.11.3.5.1 CAT classification and reference number": "trial_cat_number",
  "D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy": "trial_combination_product_has_device",
  "D.3.11.5 Radiopharmaceutical medicinal product": "trial_radiopharmaceutical_medicinal_product",
  "D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum)": "trial_immunological_medicinal_product",
  "D.3.11.7 Plasma derived medicinal product": "trial_plasma_derived_medicinal_product",
  "D.3.11.8 Extractive medicinal product": "trial_extractive_medicinal_product",
  "D.3.11.9 Recombinant medicinal product": "trial_recombinant_medicinal_product",
  "D.3.11.10 Medicinal product containing genetically modified organisms": "trial_medicinal_product_contains_gentically_modified_organisms",
  "D.3.11.11 Herbal medicinal product": "trial_contains_herbal_medicinal_product",
  "D.3.11.12 Homeopathic medicinal product": "trial_contains_homeopathic_medicinal_product",
  "D.3.11.13 Another type of medicinal product": "trial_contains_other_medicinal_product",
  "D.3.11.13.1 Other medicinal product type": "trial_other_medicinal_product_type",
  "D.8.1 Is a Placebo used in this Trial?": "trial_uses_placebo",
  "D.8.3 Pharmaceutical form of the placebo": "trial_placebo_pharmaceutical_form",
  "D.8.4 Route of administration of the placebo": "trial_placebo_administrational_route",
  "E.1.1 Medical condition(s) being investigated": "trial_medicinal_conditions",
  "E.1.1.1 Medical condition in easily understood language": "trial_medicinal_conditions_simplified",
  "E.1.1.2 Therapeutic area": "trial_therapeutic_area",
  "E.1.2 Version": "trial_version",
  "E.1.2 Level": "trial_level",
  "E.1.2 Classification code": "trial_classification_code",
  "E.1.2 Term": "trial_term",
  "E.1.2 System Organ Class": "trial_system_organ_class",
  "E.1.3 Condition being studied is a rare disease": "trial_condition_is_rare_disease",
  "E.2.1 Main objective of the trial": "trial_main_objective",
  "E.2.2 Secondary objectives of the trial": "trial_secondary_objectives",
  "E.2.3 Trial contains a sub-study": "trial_contains_sub_study",
  "E.2.3.1 Full title, date and version of each sub-study and their related objectives": "trial_full_title_and_version",
  "E.3 Principal inclusion criteria": "trial_principal_inclusion_criteria",
  "E.4 Principal exclusion criteria": "trial_principal_exclusion_criteria",
  "E.5.1 Primary end point(s)": "trial_primary_end_points",
  "E.5.1.1 Timepoint(s) of evaluation of this end point": "trial_primary_end_points_evaluation",
  "E.5.2 Secondary end point(s)": "trial_secondary_end_points",
  "E.5.2.1 Timepoint(s) of evaluation of this end point": "trial_secondary_end_points_evaluation",
  "E.6.1 Diagnosis": "trial_diagnosis",
  "E.6.2 Prophylaxis": "trial_prophylaxis",
  "E.6.3 Therapy": "trial_therapy",
  "E.6.4 Safety": "trial_safety",
  "E.6.5 Efficacy": "trial_efficacy",
  "E.6.6 Pharmacokinetic": "trial_pharmacokinetic",
  "E.6.7 Pharmacodynamic": "trial_pharmacodynamic",
  "E.6.8 Bioequivalence": "trial_bioequivalence",
  "E.6.9 Dose response": "trial_dose_response",
  "E.6.10 Pharmacogenetic": "trial_pharmacogenetic",
  "E.6.11 Pharmacogenomic": "trial_pharmacogenomic",
  "E.6.12 Pharmacoeconomic": "trial_pharmacoeconomic",
  "E.6.13 Others": "trial_has_other_scope",
  "E.6.13.1 Other scope of the trial description": "trial_other_scope",
  "E.7.1 Human pharmacology (Phase I)": "trial_is_phase1",
  "E.7.1.1 First administration to humans": "trial_has_administration_to_humans",
  "E.7.1.2 Bioequivalence study": "trial_has_bioequivalence_study",
  "E.7.1.3 Other": "trial_has_other_studies",
  "E.7.1.3.1 Other trial type description": "trial_other_type_description",
  "E.7.2 Therapeutic exploratory (Phase II)": "trial_is_phase2",
  "E.7.3 Therapeutic confirmatory (Phase III)": "trial_is_phase3",
  "E.7.4 Therapeutic use (Phase IV)": "trial_is_phase4",
  "E.8.1 Controlled": "trial_is_controlled",
  "E.8.1.1 Randomised ": "trial_is_randomised",
  "E.8.1.2 Open ": "trial_is_open",
  "E.8.1.3 Single blind ": "trial_is_single_blind",
  "E.8.1.4 Double blind ": "trial_is_double_blind",
  "E.8.1.5 Parallel group ": "trial_is_parallel_group",
  "E.8.1.6 Cross over ": "trial_is_cross_over",
  "E.8.1.7 Other ": "trial_has_other_design",
  "E.8.1.7.1 Other trial design description": "trial_other_design_description",
  "E.8.2.1 Other medicinal product(s) ": "trial_comparator_has_other_medicinal_products",
  "E.8.2.2 Placebo ": "trial_comparator_has_placebo",
  "E.8.2.3 Other ": "trial_comparator_has_other_description",
  "E.8.2.3.1 Comparator description": "trial_comparator_other_description_details",
  "E.8.2.4 Number of treatment arms in the trial": "trial_treatment_arms_number",
  "E.8.3 The trial involves single site in the Member State concerned": "trial_contains_single_site_in_member_state",
  "E.8.4 The trial involves multiple sites in the Member State concerned": "trial_contains_multiple_sites_in_member_state",
  "E.8.4.1 Number of sites anticipated in Member State concerned": "trial_number_of_sites_in_member_state",
  "E.8.5 The trial involves multiple Member States": "trial_has_multiple_member_states",
  "E.8.5.1 Number of sites anticipated in the EEA": "trial_anticipated_sites_in_eea",
  "E.8.6 Trial involving sites outside the EEA": "trial_involves_sites_outside_eea",
  "E.8.6.1 Trial being conducted both within and outside the EEA": "trial_is_within_and_outside_eea",
  "E.8.6.2 Trial being conducted completely outside of the EEA": "trial_is_completely_outside_eea",
  "E.8.6.3 If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned": "trial_sites_outside_eea",
  "E.8.7 Trial has a data monitoring committee": "trial_has_data_monitoring_committee",
  "E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial": "trial_end_definition",
  "E.8.9.1 In the Member State concerned years": "trial_duration_initial_estimate_years",
  "E.8.9.1 In the Member State concerned months": "trial_duration_initial_estimate_months",
  "E.8.9.1 In the Member State concerned days": "trial_duration_initial_estimate_years",
  "F.1.1 Trial has subjects under 18": "trial_has_subjects_under_18",
  "F.1.1 Number of subjects for this age range": "trial_number_of_subjects_under_18",
  "F.1.1.1 In Utero": "trial_has_subjects_in_utero",
  "F.1.1.1.1 Number of subjects for this age range": "trial_number_of_subjects_in_utero",
  "F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks)": "trial_has_newborn_infants",
  "F.1.1.2.1 Number of subjects for this age range": "trial_number_of_newborn_infants",
  "F.1.1.3 Newborns (0-27 days)": "trial_has_newborns",
  "F.1.1.3.1 Number of subjects for this age range": "trial_number_of_newborns",
  "F.1.1.4 Infants and toddlers (28 days-23 months)": "trial_has_infants_and_toddlers",
  "F.1.1.4.1 Number of subjects for this age range": "trial_number_of_infants_and_toddlers",
  "F.1.1.5 Children (2-11years)": "trial_has_children",
  "F.1.1.5.1 Number of subjects for this age range": "trial_number_of_children",
  "F.1.1.6 Adolescents (12-17 years)": "trial_has_adolescents",
  "F.1.1.6.1 Number of subjects for this age range": "trial_number_of_adolescents",
  "F.1.2 Adults (18-64 years)": "trial_has_adults",
  "F.1.2.1 Number of subjects for this age range": "trial_number_of_adults",
  "F.1.3 Elderly (>=65 years)": "trial_has_elderly_subjects",
  "F.1.3.1 Number of subjects for this age range": "trial_number_of_elderly_subject",
  "F.2.1 Female": "trial_has_female_subjects",
  "F.2.2 Male": "trial_has_male_subjects",
  "F.3.1 Healthy volunteers": "trial_has_healthy_volunteers",
  "F.3.2 Patients": "trial_has_patients",
  "F.3.3 Specific vulnerable populations": "trial_has_specific_vulnerable_populations",
  "F.3.3.1 Women of childbearing potential not using contraception": "trial_has_women_not_using_contraception",
  "F.3.3.2 Women of child-bearing potential using contraception": "trial_has_women_using_contraception",
  "F.3.3.3 Pregnant women": "trial_has_pregnant_women",
  "F.3.3.4 Nursing women": "trial_has_women_in_nursing_women",
  "F.3.3.5 Emergency situation": "trial_has_women_in_emergency_situation",
  "F.3.3.6 Subjects incapable of giving consent personally": "trial_has_subjects_incapable_of_giving_consent_personally",
  "F.3.3.6.1 Details of subjects incapable of giving consent": "trial_details_of_subjects_incapable_of_giving_consent",
  "F.3.3.7 Others": "trial_has_other_vulnerable_population",
  "F.3.3.7.1 Details of other specific vulnerable populations": "trial_details_of_vulnerable_population",
  "F.4.1 In the member state": "trial_subjects_in_member_state",
  "F.4.2 For a multinational trial": "trial_subjects_for_multinational_trial",
  "F.4.2.1 In the EEA": "trial_subjects_in_eea",
  "F.4.2.2 In the whole clinical trial": "trial_subjects_in_whole_clinical_trial",
  "F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)": "trial_plans_for_treatment_post_study_completion",
  "G.4 Investigator Networks to be involved in the Trial": "trial_has_investigator_networks_to_be_involved_in_the_trial",
  "G.4.1 Name of Organisation": "trial_investigator_organization_name",
  "G.4.3.4 Network Country": "trial_investigator_organization_country",
  "H.4 Third Country in which the trial was first authorised": "trial_third_country_where_trial_was_first_authorized",
  "H.4.1 First Authorised Third Country": "trial_first_authorized_third_country",
  "N. Competent Authority Decision": "trial_competent_authority_decision",
  "N. Date of Competent Authority Decision": "trial_date_of_competent_authority_decision",
  "N. Ethics Committee Opinion": "trial_ethics_committee_opinion",
  "N. Date of Ethics Committee Opinion": "trial_ethics_committee_opinion_date",
  "P. End of Trial Status": "trial_end_status",
  "P. Date of the global end of the trial": "trial_global_end_date",
  "Link": "eudract_link"
}


